Navigation Links
eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
Date:4/14/2008

PHILADELPHIA, April 14 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (Nasdaq: ERES), and nSpire Health, Inc. announced today their alliance to provide integrated Cardiac Safety and Pulmonary Core Lab Services to clinical researchers worldwide.

eResearchTechnology is a leading provider of centralized electrocardiographic (ECG), eClinical technology, ePRO, and other services to the pharmaceutical, biotechnology, medical device, and related industries. nSpire Health is a leading provider of respiratory clinical trials services, including Cardiopulmonary Exercise Testing, High Definition Pulmonary Diagnostics Systems, Spirometry, and Home Monitoring.

Under the agreement, eRT and nSpire will deliver a combined solution to meet the increased demand for cardio-pulmonary safety and efficacy services during clinical trials, in part caused by an increased interest in using inhaled therapeutics. The partnership will offer integrated services from project planning and set-up through study conduct, management, and data delivery for primary and secondary Cardiac and Respiratory clinical trial endpoints. nSpire Health will provide eSP(TM) Core Lab Data Management software, QA services, HDpft(TM), KoKo(R), PiKo(R), and PiKoLogic(TM) (electronic Diary) respiratory diagnostic measuring instruments. eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT 2.0 workflow-enabled data management system.

"This alliance addresses a growing need in clinical research to offer comprehensive, best in class services in these two closely related areas of clinical study," said Michael McKelvey, President and CEO of eRT. "While many sponsors recognize and source each company for its respective area of expertise, customers increasingly seek consolidation and streamlining in all phases of a clinical trial. eRT and nSpire Health approach the market in the same way -- focusing on scientific excellence, providing a quality product, and client satisfaction. We are both metrics driven and process oriented to ensure on-time, on-budget, reliable data delivery on a global scale."

"Clinical trial sponsors have a strategic need to deliver accurate, cost- effective results in less time. They need therapeutic specialists that they can trust. This partnership leverages the world's most advanced Cardio- Respiratory specific technologies and data management services from each company into one unified source, reducing costs and accelerating time to market for emerging inhaled therapeutic trials," commented Michael S. Sims, President and CEO of nSpire Health, Inc.

About nSpire Health

nSpire Health develops and manufactures respiratory care products and provides related services in over 100 countries. The company is focused on cardiopulmonary diagnostics, respiratory core lab services, and disease management solutions designed to improve health care productivity while increasing the overall quality of patient care. nSpire Health is the exclusive provider of PiKo(R) home health monitors and HDpft(TM) systems, the most accurate and precise pulmonary function testing systems worldwide.

About eRT

Based in Philadelphia, Pa, eResearchTechnology, Inc. (http://www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2008 financial guidance, involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
2. Sticky mussels inspire biomedical engineer yet again
3. Good Neighbor Pharmacy(R) Ironman Competitor Inspires Individuals with Diabetes to Live Without Limits
4. MIT creates gecko-inspired bandage
5. Nanotechs health, environmental impacts worry scientists and the public
6. ETEX and LifeNet Health, Inc. Enter Agreement
7. IBF/LifeScience Alley MedTech Investing Conference Adds Ashley Boam, Acting Deputy Director for Science and Review Policy, Office of Device Evaluation, Center for Devices and Radiological Health, FDA
8. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
9. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
10. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
11. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Global demand for enzymes is forecast to ... $7.2 billion.  This market includes enzymes used in ... production, animal feed, and other markets) and specialty ... and beverages will remain the largest market for ... products containing enzymes in developing regions.  These and ...
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
Breaking Biology Technology:
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):